Overview

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

Status:
Terminated

Trial end date:
2021-05-06

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of of coronavirus disease 2019 (COVID-19) related hospitalization or all-cause death in non-hospitalized participants with early stage COVID-19 and to evaluate the safety of RDV administered in an outpatient setting.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Remdesivir